These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34641935)

  • 1. Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.
    Hamed A; An Haack K; Gwaltney C; Baranowski E; Stewart A; Krupnick R; Tyler M; Sparks S; Paty J
    Orphanet J Rare Dis; 2021 Oct; 16(1):428. PubMed ID: 34641935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom.
    Hubig L; Sussex AK; MacCulloch A; Hughes D; Graham R; Morris L; Raza S; Lloyd AJ; Sowinski A; Gallop K
    J Health Econ Outcomes Res; 2023; 10(1):41-50. PubMed ID: 36883056
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a Conceptual Model of Physical Functioning Limitations Experienced by Patients with Late-Stage Chronic Kidney Disease: A Qualitative Interview Study.
    Palmer E; Johar I; Little DJ; Karlsson N
    Adv Ther; 2024 Jul; 41(7):2757-2775. PubMed ID: 38722538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.
    Wenninger S; Greckl E; Babačić H; Stahl K; Schoser B
    J Neurol; 2019 Jan; 266(1):133-147. PubMed ID: 30430231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new patient-reported outcome measure for complex cryptoglandular fistulas (20-Item complex cryptoglandular fistula questionnaire
    McCurdy JD; Crooks P; Gwaltney C; Krupnick R; Cadogan KA; Karki C
    J Patient Rep Outcomes; 2024 Aug; 8(1):99. PubMed ID: 39172310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis.
    Flythe JE; Karlsson N; Sundgren A; Cordero P; Grandinetti A; Cremisi H; Rydén A
    BMC Nephrol; 2021 Jun; 22(1):233. PubMed ID: 34162354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
    Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
    Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.
    Holmstrom S; Naidoo S; Turnbull J; Hawryluk E; Paty J; Morlock R
    Patient; 2019 Feb; 12(1):57-67. PubMed ID: 30519830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the Fabry Disease Patient-Reported Outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease.
    Hamed A; DasMahapatra P; Lyn N; Gwaltney C; Hopkin RJ
    Orphanet J Rare Dis; 2021 Jun; 16(1):285. PubMed ID: 34172077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
    Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
    Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
    Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives.
    Rofail D; Somersan-Karakaya S; Choi JY; Przydzial K; Zhao Y; Hussein M; Norton TD; Podolanczuk AJ; Mylonakis E; Geba GP
    BMJ Open; 2024 Jan; 14(1):e076992. PubMed ID: 38233059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature.
    Hobson-Webb LD; Proia AD; Thurberg BL; Banugaria S; Prater SN; Kishnani PS
    Mol Genet Metab; 2012 Aug; 106(4):462-9. PubMed ID: 22664150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward deconstructing the phenotype of late-onset Pompe disease.
    Schüller A; Wenninger S; Strigl-Pill N; Schoser B
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):80-8. PubMed ID: 22253010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Patient Experience with Diabetic Retinopathy: Qualitative Analysis of Patients with Proliferative Diabetic Retinopathy.
    Sherman SA; Rofail D; Levine A; Hartford CR; Baldasaro J; Marquis P; Rao R; Do DV
    Ophthalmol Ther; 2023 Feb; 12(1):431-446. PubMed ID: 36460939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic and clinical studies in patients with late-onset Pompe disease and lower urinary tract symptoms.
    Kuchenbecker KS; Kirschner-Hermanns R; Kornblum C; Jaekel A; Anding R; Kohler A
    Neurourol Urodyn; 2020 Jun; 39(5):1437-1446. PubMed ID: 32343026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the patient experience of chronic kidney disease stages 2-3b: a qualitative interview study with Kidney Disease Quality of Life (KDQOL-36) debrief.
    Rydén A; Nolan S; Maher J; Meyers O; Kündig A; Bjursell M
    BMC Nephrol; 2022 Jun; 23(1):201. PubMed ID: 35641914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
    Meznaric M; Fumic K; Leonardis L
    J Clin Pathol; 2019 Jul; 72(7):468-472. PubMed ID: 30878973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.